Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as a targeted therapy for the treatment of people who has cancer. It represents an innovative therapeutic application that includes the unique, high specificity and antitumor activity of monoclonal antibodies which are tumor-specific but not very cytotoxic, with the cell killing activity of small molecule drugs that are too toxic to be used on their own. Scientists could optimize the features of both components by linking monoclonal antibodies with cytotoxic agents.
BOC Sciences is the industry leading expert in small molecular and antibody engineering, also our rich experience could help us to provide comprehensive services for the conjugation and characterization of Antibody-Drug Conjugates. With years of experience in the variety of organic synthesis and binding assays, we provide comprehensive expertise to support the development of antibody-drug conjugate products for all phases of drug development from discovery to GMP manufacturing.
As ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug, an ideal ADC has:
BOC Sciences’ integrated capabilities for development of antibody-drug conjugates: